Adicet Bio
Clinical trials sponsored by Adicet Bio, explained in plain language.
Adicet Bio
ACET
NASDAQ
Clinical-stage biotech developing engineered gamma-delta T cell therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on lupus and scleroderma in early trial Results expected Dec 2026 (estimated)
- Engineered immune cells target CD70 in kidney cancer Results expected Dec 2026 (estimated)
- Engineered immune cells take on stubborn arthritis in early trial Results expected Mar 2027 (estimated)